Feminizing Hormone Replacement Therapy for MtF Transition

Episode 9

Feminizing Hormone Therapy for MtF Transition

In Episode 9, Erin Everett, NP-C, gives an overview of Feminizing Hormone Therapy medications for a Male to Female MtF Transition. Erin discusses the prescribing guidelines for, and the expected effects of, feminizing hormones 17 beta-Estradiol, Estradiol Valerate, and Estradiol Cypionate. She also covers the risks, side effects, and benefits of Spironolactone and Progesterone.

About This Episode

In episode nine of Exclusively Inclusive, Erin Everett, NP-C, provides an in-depth overview of Feminizing Hormone Therapy for a MtF Transition.

During the episode, your host discusses the uses and differences between bioidentical feminizing hormones 17 beta-Estradiol, Estradiol Valerate, and Estradiol Cypionate. She covers the prescribing guidelines and expected effects of each of these feminizing hormones, as well as:

  • the administration (oral vs. intramuscular injection)
  • benefits of dosing twice daily (energy levels, libido, mood, etc.)
  • potential risks, benefits, and side effects of their use

Further on in the episode, Erin discusses the popular androgen blocker Spironolactone and its dosing, benefits, risks, and side effects including increased urination and fatigue.

Rounding out episode nine, Erin covers the use of Progesterone for MtF Transitions, as it is not a key player in feminizing, but has several anecdotal benefits to a MtF transition such as softening of the skin, reduction of terminal hair growth, weight distribution, and promotion of breast tissue and areola development.

Episode Links:

Feminizing Hormone Therapy for MtF Transition